NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal<
04 Mar 2022

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

This key addition will strengthen the Ysios Capital team, which is currently investing its fund Ysios BioFund III.
Galecto Reports Financial Results for the Year Ended December 31, 2021<
17 Feb 2022

Galecto Reports Financial Results for the Year Ended December 31, 2021

Continued pipeline progress with three potentially first-in-class product candidates
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline<
16 Feb 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Largest Series A round for a Spanish biotech company.
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease<
02 Feb 2022

NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

SEFA-6179 is NST’s third programme to enter the clinic.
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer<
01 Feb 2022

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic
Lava Therapeutics annouces participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022<
28 Jan 2022

Lava Therapeutics annouces participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

Access to the recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics website.
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care<
27 Jan 2022

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury<
26 Jan 2022

AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury

The article provides insights on important advances in the understanding of AKI as a disease spectrum with an urgent need for new treatments.
LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference<
18 Jan 2022

LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference

New non-human primate data support the safety and tolerability profile of LAVA’s lead solid tumor GammabodyTM programs

Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer<
05 Jan 2022

Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

Dr. Oestreich brings extensive experience in business and drug development

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.